GSA Capital Partners LLP Cuts Stock Position in Allogene Therapeutics, Inc. $ALLO

GSA Capital Partners LLP cut its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 62.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 182,879 shares of the company’s stock after selling 309,242 shares during the period. GSA Capital Partners LLP’s holdings in Allogene Therapeutics were worth $227,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ALLO. Goldman Sachs Group Inc. boosted its stake in Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after buying an additional 3,747,397 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Allogene Therapeutics by 578.7% during the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after acquiring an additional 952,158 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Allogene Therapeutics by 16.0% in the 2nd quarter. Primecap Management Co. CA now owns 5,719,140 shares of the company’s stock worth $6,463,000 after acquiring an additional 787,300 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Allogene Therapeutics by 9.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,020,770 shares of the company’s stock valued at $11,186,000 after purchasing an additional 761,642 shares in the last quarter. Finally, Aberdeen Group plc boosted its stake in shares of Allogene Therapeutics by 82.4% in the 3rd quarter. Aberdeen Group plc now owns 1,582,265 shares of the company’s stock valued at $1,962,000 after purchasing an additional 715,015 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Performance

ALLO opened at $2.78 on Friday. Allogene Therapeutics, Inc. has a 52-week low of $0.86 and a 52-week high of $2.80. The stock has a market capitalization of $624.75 million, a PE ratio of -2.84 and a beta of 0.60. The stock’s 50 day moving average price is $1.71 and its 200-day moving average price is $1.41.

Insider Activity at Allogene Therapeutics

In other news, CFO Geoffrey M. Parker sold 24,001 shares of Allogene Therapeutics stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $1.76, for a total transaction of $42,241.76. Following the sale, the chief financial officer owned 1,252,795 shares of the company’s stock, valued at approximately $2,204,919.20. The trade was a 1.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Zachary Roberts sold 35,700 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $1.77, for a total transaction of $63,189.00. Following the transaction, the executive vice president owned 581,166 shares in the company, valued at $1,028,663.82. This represents a 5.79% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 215,855 shares of company stock worth $378,426. 13.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Citigroup raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, January 9th. UBS Group started coverage on Allogene Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $8.00 target price for the company. Wall Street Zen upgraded Allogene Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, February 22nd. Finally, Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Friday, January 9th. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Allogene Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $8.40.

Allogene Therapeutics Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.